A healthy run of nine-figure private rounds for biotechs in the US has continued with an impressive $225 million Series B for immunotherapy specialist AltruBio.
In a new white paper from the World Without Disease initiative, a 2024 update is provided of the current endeavours and developments that have occurred since inaugural discussions last year